Absolutely, but that depends on the NHS, which is a very complex system, not on the doctors. If the NHS policy is creating a niche for private companies, it is certainly not their fault.
Private companies need money to survive, but prices often drop when fair competition is established. The problem is precisely the lack of fair competition, especially in the pharmaceutical sector, which is fundamental for medical care in a highly medicalised society like ours. For example, the newly formed Theramex UK, which holds the rights to sell the Evorel and FemSeven patches in the UK, among other products, was owned by the British private equity company CVC, but has just been bought by American/French partners (Carlyle /PAI). Who knows how this is going to influence the price concessions given by the DHSC to their products for NHS doctors and pharmacies?
